These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 38235832)

  • 1. Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins.
    Wang YC; Ji P; Hariharan S; Wang J; Okusanya O; AbuAsal B; Zhu H; Madabushi R; Huang SM; Zineh I
    Clin Pharmacol Ther; 2024 Mar; 115(3):440-451. PubMed ID: 38235832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Clinical Pharmacology Principles in Drug Development of Modified-Release Products: Leveraging Exposure-Response Information to Support Approval.
    AbuAsal BS; Hamed SS; Ahmed MA; Al-Mansour L; Uppoor R; Mehta M
    J Clin Pharmacol; 2020 Nov; 60(11):1441-1452. PubMed ID: 32453882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B-Cell Hematological Malignancies.
    Jamois C; Gibiansky E; Gibiansky L; Chavanne C; Morcos PN; McIntyre C; Barrett M; Lundberg L; Zharkov A; Boehnke A; Frey N
    Clin Pharmacol Ther; 2021 Nov; 110(5):1261-1272. PubMed ID: 34041738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Drug Antibody Incidence Comparison of Therapeutic Proteins Administered Via Subcutaneous vs. Intravenous Route.
    Felderman J; Ramaiah L; Vazquez-Abad MD; Messing D; Chen Y
    AAPS J; 2024 May; 26(3):60. PubMed ID: 38730115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Delivery of Therapeutic Proteins and Peptides: An Overview of Current Technologies and Recommendations for Bridging from Approved Intravenous or Subcutaneous Administration to Novel Oral Regimens.
    Philippart M; Schmidt J; Bittner B
    Drug Res (Stuttg); 2016 Mar; 66(3):113-20. PubMed ID: 26536331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics.
    Ait-Oudhia S; Wang YM; Dosne AG; Roy A; Jin JY; Shen J; Kagan L; Musuamba FT; Zhang L; Kijima S; Gastonguay MR; Ouellet D
    Clin Pharmacol Ther; 2024 Mar; 115(3):412-421. PubMed ID: 38069528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
    Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
    Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.
    Bi Y; Liu J; Furmanski B; Zhao H; Yu J; Osgood C; Ward A; Keegan P; Booth BP; Rahman A; Wang Y
    Ann Oncol; 2019 Apr; 30(4):644-651. PubMed ID: 30715147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective.
    Liu T; Neuner R; Thompson A; Pottackal G; Petullo D; Liu J; Nikolov N; Sahajwalla C; Doddapaneni S; Chen J
    Lupus; 2022 Apr; 31(4):424-432. PubMed ID: 35238725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?
    Tu CL; Wang YL; Hu TM; Hsu LF
    BioDrugs; 2019 Aug; 33(4):437-446. PubMed ID: 31111423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bridging the Gap With Clinical Pharmacology in Innovative Rare Disease Treatment Modalities: Targeting DNA to RNA to Protein.
    Lee L; Gollen R; Fathallah AM; Gao L; Patil S
    J Clin Pharmacol; 2022 Dec; 62 Suppl 2():S95-S109. PubMed ID: 36461740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doses Evaluated in Clinical Pharmacology Studies Investigating the Effect of Intrinsic and Extrinsic Factors on PK and Safety: Case Examples from Approved Drug Development Programs.
    Kaspera R; Shitara Y
    AAPS J; 2024 Jun; 26(4):71. PubMed ID: 38886275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
    Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
    Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No Smoke without Tobacco: A Global Overview of Cannabis and Tobacco Routes of Administration and Their Association with Intention to Quit.
    Hindocha C; Freeman TP; Ferris JA; Lynskey MT; Winstock AR
    Front Psychiatry; 2016; 7():104. PubMed ID: 27458388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational and pharmacokinetic-pharmacodynamic application for the clinical development of GDC-0334, a novel TRPA1 inhibitor.
    Chan P; Ding HT; Liederer BM; Mao J; Belloni P; Chen L; Gao SS; Joseph V; Yang X; Lin JS; Mitra MS; Putnam WS; Quartino A; Bauer RN; Pan L
    Clin Transl Sci; 2021 Sep; 14(5):1945-1954. PubMed ID: 34058071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Assessment of US Food and Drug Administration Dosing Recommendations For Drug Development Programs Amenable to Response-Guided Titration.
    Wang L; Maxfield K; Guinn D; Madabushi R; Zineh I; Schuck RN
    Clin Pharmacol Ther; 2021 Jan; 109(1):123-130. PubMed ID: 33022770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.
    Downing NS; Aminawung JA; Shah ND; Krumholz HM; Ross JS
    JAMA; 2014 Jan 22-29; 311(4):368-77. PubMed ID: 24449315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.